Fountain Healthcare Partners
Fountain Healthcare Partners (FHP) is a life-science focused venture capital firm that provides equity capital and sector expertise to entrepreneurs building specialty pharma, biopharmaceuticals, medical device and diagnostics companies. FHP manages multiple funds (three funds reported; €301M AUM), focuses primarily on Europe with US activity, limits the number of active portfolio companies to provide hands-on support, and partners with co-investors to lead or co-lead syndicates.
Industries
Nr. of Employees
small (1-50)
Fountain Healthcare Partners
Two Docklands Central, Level 4, Guild Street, IFSC, Dublin, D01 K2C5, Ireland
Portfolio
FHP led or participated in multiple financings (including a $70M private placement in 2009) and supported AMR101 through Phase 3 development. Company reported positive MARINE Phase 3 results (Nov 2010) and advanced NDA planning for AMR101 in 2011. FHP partners were active at board level during development milestones.
#Biopharmaceuticals (cardiovascular)
FHP co-led a $17.3M Series C financing in June 2009 (with Mitsui & Co. Venture Partners) to support launch of the Sideguard™ Sidebranch stent in Europe. FHP also participated in the first tranche of a €10.5M Series D investment in November 2010 to support expanded launches, manufacturing capacity and R&D.
#Medical devices (coronary stents)
FHP participated in XyloCor's Series B financing (reported $67.5M) to advance XC001 into Phase 2b (EXACT-2) and other trials. XC001 is a one-time adenoviral gene therapy administered via catheter (Extroducer® system) to promote angiogenesis in refractory angina; the company completed positive Phase 1/2 results and progressed to randomized Phase 2 trials.
#Biopharmaceuticals / Gene therapy (cardiovascular)
FHP is an investor; company progressed PerQseal® and PerQseal® Elite through CE approvals and U.S. IDE/PMA submissions, and secured a €30M strategic investment from Haemonetics in 2023. Vivasure reported positive PATCH pivotal study results and submitted a U.S. PMA for PerQseal Elite.
#Medical devices (vascular closure)
FHP-backed company; NEUROMARK® Next Generation system received FDA 510(k) clearance enabling U.S. commercial validation and expanded product features including real-time feedback for electrode placement.
#Medical devices (ENT; neurostimulation for chronic rhinitis)
FHP participated in an oversubscribed €10M financing to accelerate commercialisation; Lenire received FDA De Novo authorization (March 2023) and has published pivotal clinical trial results and real-world evidence supporting its use.
#Medical devices / Neurostimulation (tinnitus)
FHP led or participated in multiple financings (including a $70M private placement in 2009) and supported AMR101 through Phase 3 development. Company reported positive MARINE Phase 3 results (Nov 2010) and advanced NDA planning for AMR101 in 2011. FHP partners were active at board level during development milestones.
#Biopharmaceuticals (cardiovascular)
FHP co-led a $17.3M Series C financing in June 2009 (with Mitsui & Co. Venture Partners) to support launch of the Sideguard™ Sidebranch stent in Europe. FHP also participated in the first tranche of a €10.5M Series D investment in November 2010 to support expanded launches, manufacturing capacity and R&D.
#Medical devices (coronary stents)
FHP participated in XyloCor's Series B financing (reported $67.5M) to advance XC001 into Phase 2b (EXACT-2) and other trials. XC001 is a one-time adenoviral gene therapy administered via catheter (Extroducer® system) to promote angiogenesis in refractory angina; the company completed positive Phase 1/2 results and progressed to randomized Phase 2 trials.
#Biopharmaceuticals / Gene therapy (cardiovascular)
FHP is an investor; company progressed PerQseal® and PerQseal® Elite through CE approvals and U.S. IDE/PMA submissions, and secured a €30M strategic investment from Haemonetics in 2023. Vivasure reported positive PATCH pivotal study results and submitted a U.S. PMA for PerQseal Elite.
#Medical devices (vascular closure)
FHP-backed company; NEUROMARK® Next Generation system received FDA 510(k) clearance enabling U.S. commercial validation and expanded product features including real-time feedback for electrode placement.
#Medical devices (ENT; neurostimulation for chronic rhinitis)
FHP participated in an oversubscribed €10M financing to accelerate commercialisation; Lenire received FDA De Novo authorization (March 2023) and has published pivotal clinical trial results and real-world evidence supporting its use.
#Medical devices / Neurostimulation (tinnitus)